Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A 52-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Monotherapy
The primary objective of this study will be to show the superiority of saxagliptin compared to glimepiride in bringing elderly patients (≥65 years) with type 2 diabetes to HbA1c target <7% without hyp...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A study to evaluate the effect of Rosuvastatin on fatty acids in Children and Adolescents with Homozygous Familial Hypercholesterolemia
To assess the efficacy of rosuvastatin 20 mg on low density lipoprotein cholesterol (LDL C), compared to placebo, after 6 weeks of treatment in pediatric patients with Homozygous Familial Hypercholest...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca UK Ltd
MAJ Il y a 5 ans
Quetiapine Augmentation In Treatment-Resistant Depression – An Open Pilot Study
To determine the efficacy of quetiapine in the treatment of depression at 8 weeks, assessed by calculation of the proportion of subjects responding by week 8, derived from the change in Montgomery Asb...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB, European Regulatory Affairs
MAJ Il y a 5 ans
A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function
The primary objective of this study is to determine the onset and offset of antiplatelet effect of AZD6140 compared to clopidogrel by evaluation of: • The percent inhibition of platelet aggregation (I...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Arrow Therapeutics Ltd. (a member of the AstraZeneca group of companies)
MAJ Il y a 5 ans
A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1b Infection with Compensated Liver Disease
To determine the Rapid Virologic Response (RVR) of multiple oral doses of AZD7295 in conjunction with standard of care (SoC) in patients with chronic hepatitis C virus genotype 1b infection.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600 mg dose) and Lithium as Monotherapy in Adult Patients with Bipolar Depression for 8 weeks and Quetiapine in Continuation Treatment for 26 up to 52 weeks
To demonstrate superior efficacy of quetiapine compared with placebo in the acute treatment of patients with bipolar depression.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment Elevation Acute Coronary Syndromes - DISPERSE2 - TIMI33
The primary objective of this study is to assess the safety and tolerability of different doses of AZD6140 in the presence of acetyl salicylic acid (ASA), compared with clopidogrel plus ASA in patient...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A 4 week randomised, double blind, placebo controlled, parallel group, phase II, PoP study to assess the efficacy and safety of AZD1981 in adult patients with asthma
The primary objective of the study is to compare the clinical efficacy of twice daily, orally administrated AZD1981 with that of placebo over a 4-week treatment period in adults with persistent asthma...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Randomised, Double-blind, Parallel-group, Multicentre, Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 250 mg, Fulvestrant (FASLODEX™) 250 mg (plus 250 mg Loading regimen) and Fulvestrant (FASLODEX™) 500 mg in Postmenopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing after Previous Endocrine Therapy
To evaluate the objective response rate (ORR) of patients treated with fulvestrant 250 mg, fulvestrant 250 mg (plus 250 mg loading regimen) and fulvestrant 500 mg.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 5 ans
A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of AZD3480 in Schizophrenic Patients on Stable Antipsychotic Monotherapy with quetiapine, risperidone or olanzapine
To investigate the safety and tolerability of multiple ascending oral doses of AZD3480 when administered to schizophrenic patients on stable antipsychotic monotherapy with either quetiapine, risperido...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
28
29
30
31
32
33
34
35
36
37
Suivant